Article
Phase II trial of temsirolimus in patients with metastatic breast cancer.
Breast cancer research and treatment - 1 Nov 2012
Fleming Gini F, Ma Cynthia X, Huo Dezheng, Sattar Husain, Tretiakova Maria, Lin L, Hahn Olwen M, Olopade F O, Nanda R, Hoffman Philip C, Naughton M J, Pluard Timothy, Conzen Suzanne D, Ellis Matthew J
Abstract excerpt
Preclinical models suggested that activating mutations of the PIK3CA gene are associated with sensitivity to inhibitors of the mammalian target of rapamycin (mTOR). In breast cancers, PIK3CA mutations are associated with estrogen receptor (ER) positivity. We therefore performed an open-label single arm phase II study of the rapamycin analog, temsirolimus, at a dose of 25 mg weekly, in women with pretreated breast...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.